We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Nepexto

News List

Lupin and Mylan launch Nepexto, biosimilar etanercept in German market expresspharma
August 27, 2020
Etanercept was first approved for the treatment of rheumatoid arthritis in Germany in 2000 and since then has offered an effective treatment option for several chronic inflammatory diseases.
Lupin and Mylan receive European Marketing Authorization for Nepexto, Biosimilar Etanercept expresspharma
June 05, 2020
A a phase 3 clinical study in patients with moderate-to-severe active rheumatoid arthritis confirmed equivalence of Nepexto to Enbrel in terms of efficacy, safety and immunogenicity.
Mylan, Lupin Announce Positive CHMP Opinion for Biosimilar Nepexto americanpharmaceuticalreview
April 01, 2020
Mylan and Lupin announced the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of Nepexto® ...